Global Pharma and Biotech Dealmaking Royalty Rate Trends Report 2021

Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021" report has been added to ResearchAndMarkets.com's offering.

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

Key benefits

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 provides the reader with the following key benefits:

• In-depth understanding of royalty rate partnering deal trends since 2010

• Analysis of the structure of royalty clauses with numerous real life case studies

• Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release

• Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed

• Insight into the royalty terms included in a licensing agreement, together with real world clause examples

• Understand the key deal terms companies have agreed in previous deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 includes:

• Trends in royalty rates in the biopharma industry since 2010

• Analysis of royalty rate clause structure

• Case studies of real-life licensing deals which disclose royalty rates

• Comprehensive listing of licensing deals which disclose royalty rates since 2010

• Access to licensing contract documents which disclose royalty rates

• The leading licensing deals by royalty rate value since 2010

• Most active royalty rate disclosures since 2010

In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 available deals and contracts are listed by:

• Company A-Z

• Headline value

• Therapeutic area

• Technology type

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?

• What is actually granted by the agreement to the partner company?

• What exclusivity is granted?

• What is the payment structure for the deal?

• How are sales and payments audited?

• What is the deal term?

• How are the key terms of the agreement defined?

• How are IPRs handled and owned?

• Who is responsible for commercialization?

• Who is responsible for development, supply, and manufacture?

• How is confidentiality and publication managed?

• How are disputes to be resolved?

• Under what conditions can the deal be terminated?

• What happens when there is a change of ownership?

• What sublicensing and subcontracting provisions have been agreed?

• Which boilerplate clauses does the company insist upon?

• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

• Which jurisdiction does the company insist upon for agreement law?

For more information about this report visit https://www.researchandmarkets.com/r/l4ip8q

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900